Inventia Life

Inventia Life Science is a biotech company specializing in 3D bioprinting technology for biomedical research and regenerative medicine applications. The company has developed a proprietary platform called RASTRUM, which enables efficient and powerful bioprinting of 3D cell-based assays. RASTRUM's drop-on-demand digital bioprinting technology prints tiny droplets of cells and matrix components precisely and gently, allowing the creation of complex 3D cell constructs at high throughput.

Inventia's bioprinting platform offers a scalable and reproducible approach to generate advanced 3D cell models that closely mimic human tissues and organs. This technology holds significant potential in drug discovery by providing more physiologically relevant in vitro models for preclinical screening, bridging the gap between traditional 2D cell cultures and animal studies. Pharmaceutical companies can leverage RASTRUM to test new drug candidates in a 3D cellular environment, potentially reducing the risk of failure in human clinical trials. As of February 2023, four of the top ten global pharmaceutical companies utilized RASTRUM for their drug discovery programs.

In October 2022, Inventia opened its first US facility in Wilmington, Delaware, marking its expansion into the American market. The company aims to have a workforce of 150 employees by the end of 2024 to support its growing global customer base. In December 2022, Inventia secured support from the New South Wales government's Jobs Plus Program to establish a new advanced manufacturing hub in Sydney, boosting its local manufacturing capacity for global commercial expansion.